

The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.

Supplementary Data Table - Baseline, Demographic, Operative, Microbiological, Treatment, and Outcome Data for Revisions with 1 UPC versus ≥2 UPC			
Variable	1 UPC (n = 74)	≥2 UPC (n = 35)	P value
Age (years)*	73.0 (63.8 to 82.0)	69.0 (59 to 80)	0.185 ^a
Sex, F/M, n (%)	39/35 (52.7/47.3)	15/20 (42.9/57.1)	0.337 ^b
BMI (kg/m ²)*	28.1 (24.8 to 33.7)	30.0 (25.1 to 33.2)	0.664 ^a
ASA classification, n (%)			0.571 ^c
1	0	0	
2	15 (20.3)	10 (28.6)	
3	47 (63.5)	19 (54.3)	
4	12 (16.2)	6 (17.1)	
Diabetes, n (%)	22 (29.7)	6 (17.1)	0.160 ^b
Inflammatory condition, n (%)	12 (16.2)	2 (5.7)	0.218 ^c
Etiology for primary THA, n (%)			0.917 ^b
Osteoarthritis	50 (60.7)	24 (68.6)	
Other	24 (39.3)	11 (31.4)	
Reasons for revision, n (%)			0.940 ^c
Aseptic loosening	32 (43.2)	16 (45.7)	
Instability	10 (13.5)	6 (17.1)	
Polyethylene wear +/- osteolysis	15 (20.3)	7 (20.0)	
Periprosthetic fracture	10 (13.5)	3 (8.6)	
Adverse metal reaction	6 (8.1)	2 (5.7)	
Other	1 (1.4)	1 (2.9)	
History of previous THA revision in study joint, n (%)	20 (27.0)	14 (40.0)	0.172 ^b
Age of prosthesis (years)*	9.0 (2.1 to 17.0)	9.0 (3.6 to 22)	0.393 ^a
History of PJI in study joint, n (%)	3 (4.1)	2 (5.7)	0.655 ^c
Pre-operative serum CRP > 10mg/L, n (%)	14 (18.9)	6 (17.1)	0.828 ^b
Pre-operative serum ESR > 30mm/h, n (%)	16 (21.6)	5 (14.3)	0.348 ^b
Preoperative joint aspirate, n (%)	13 (17.6)	10 (28.6)	0.189 ^b
Type of revision, n (%)			0.551 ^b
Modular exchange	24 (32.4)	12 (34.3)	
1-component	44 (59.5)	18 (51.4)	
2-component	6 (8.1)	5 (14.3)	
Number of samples taken in study revision*	3.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)	0.056 ^a
Swab used for culture in revision, n (%)	51 (68.9)	21 (60.0)	0.359 ^b
Fluid used for culture in revision, n (%)	9 (12.2)	7 (20.0)	0.280 ^b
Tissue used for culture in revision, n (%)	64 (86.5)	29 (82.9)	0.617 ^b
UPC broth or solid, n (%)			0.837 ^b
Broth	27 (36.5)	35 (38.0)	
Solid	47 (63.5)	57 (62.0)	
Microorganisms, n (%)†			0.002 ^c
<i>C. acnes</i>	35 (46.1)	29 (30.9)	
MRSE	3 (3.9)	19 (20.2)	
MSSE	7 (9.2)	9 (9.6)	
Other CNS	12 (15.8)	7 (7.4)	
<i>Micrococcus</i> sp	2 (2.6)	6 (6.4)	
MSSA	0	4 (4.2)	
<i>Streptococcus</i> sp	5 (6.6)	4 (4.2)	
<i>Enterococcus</i> sp	1 (1.3)	4 (4.2)	
<i>Corynebacterium</i> sp	1 (1.3)	4 (4.2)	

<i>Pseudomonas aeruginosa</i>	0	3 (3.2)	
Others	10 (13.2)	5 (5.3)	
Number of revisions resistant UPC, n (%)	3 (4.1)	10 (28.6)	0.001 ^c
Antibiotic treatment of UPC, n (%)	15 (20.3)	26 (74.3)	0.000 ^b
Antibiotic route, n (%)			0.258 ^c
Oral alone	6 (40)	4 (15.4)	
IV alone	3 (20)	6 (23.1)	
Combined IV and oral	6 (40)	16 (61.5)	
Antibiotic duration, n (%)			0.096 ^c
≤6 weeks	11 (73.3)	8 (30.8)	
>6 weeks to 3 months	1 (6.7)	3 (11.5)	
>3 months to 6 months	2 (13.3)	5 (19.2)	
>6 months to 1 year	0	2 (7.7)	
Chronic/lifelong suppression	1 (6.7)	8 (30.8)	
Subsequent aseptic revision, n (%)‡	8 (10.8)	1 (2.9)	0.267 ^c
Subsequent PJI, n (%)	8 (10.8)	3 (8.6)	1.000 ^c
Time to subsequent PJI (years)*	1.0 (0.1 to 3.1)	0.58 (0.1 to 1.1)	0.766 ^a
Subsequent PJI microorganism, n (%)			0.024 ^c
Same as UPC microorganism	1 (12.5)	3 (100)	
Different than UPC microorganism	6 (75.0)	0	
Mixed	1 (12.5)	0	

*Values are median (interquartile ranges). †Reported as microorganism(s) grown from each intraoperative specimen that was positive (UPC). ‡Subsequent aseptic revision after the study revision, censored out of survival analysis once occurs as subsequent PJI could be caused by subsequent aseptic revision. ^aWilcoxon's rank-sum test. ^bPearson's chi-squared test. ^cFisher's exact test. UPC, unexpected positive intraoperative cultures; F, female; M, male; BMI, body mass index; ASA, American society of anesthesiologists; THA, total hip arthroplasty; PJI, periprosthetic joint infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; *C. acnes*, *Cutibacterium acnes*; MRSE, methicillin-resistant *Staphylococcus epidermidis*; MSSSE, methicillin-sensitive *Staphylococcus epidermidis*; CNS, coagulase-negative *Staphylococcus* species; sp, species; MSSA, methicillin-sensitive *Staphylococcus aureus*; IV, intravenous.